Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
Human intravenous immunoglobulin (IVIG) solutions were prepared by two different methods and compared to each other. The crude immunoglobulin fraction obtained from Cohn-Oncley fractionation of plasma was further purified and subjected to virus inactivation, either by polyethylene glycol precipitation and pasteurization at 60 degrees C for 10 hours, or by ion exchange chromatography and solvent/detergent treatment. The final preparations, formulated in 5% immunoglobulin solutions were characterized by in vitro analyses of biochemical and biological properties and compared with the samples of other manufacturer's IVIG solution products. The critical properties evaluated in this study were purity, molecular intactness, and the biological functions such as Fc function and anticomplementary activity. Virus inactivation and removal by processing steps and by deliberate virucidal steps, as described above, were tested on various human pathogenic viruses, such as human immunodeficiency and experimental model viruses. The tested viruses were successfully inactivated and removed. We conclude that the intravenous immunoglobulins prepared by two different methods, as described above, provide an equivalent viral safety and quality.
Chang
C E
CE
Korea Green Cross Corporation, Yongin, Kyunggi-do.
Eo
H G
HG
Lee
Y S
YS
Chung
S K
SK
Shin
J S
JS
Lah
Y K
YK
Park
C W
CW
Jung
J T
JT
Huh
J W
JW
Lee
S M
SM
D000906:Antibodies / Q000097:blood* / Q000737:chemistry / Q000378:metabolism; D001681:Biological Assay; D005591:Chemical Fractionation / Q000379:methods; D011232:Chemical Precipitation; D002851:Chromatography, High Pressure Liquid; D003165:Complement System Proteins / Q000378:metabolism; D003902:Detergents; D004591:Electrophoresis, Polyacrylamide Gel; D000431:Ethanol; D005374:Filtration; D006388:Hemagglutinins / Q000032:analysis; D006358:Hot Temperature; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification*; D015203:Reproducibility of Results; D018406:Virus Physiological Phenomena
D000906:Antibodies; D003902:Detergents; D006388:Hemagglutinins; D016756:Immunoglobulins, Intravenous; D000431:Ethanol; D003165:Complement System Proteins